CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

This was the stock's third consecutive day of losses.

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging drugs, market share of individual therapies, and ...

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1) ...

Global active pharmaceutical ingredients (API) market will reach $ 386.2 billion by 2032, growing by 6.4% annually over 2022-2032, driven by rising adoption of biologics in disease management, ...